INTRODUCTION {#SEC1}
============

Transcription, the first step in gene expression, is highly regulated by a multitude of transcription factors. The core transcription machinery is RNA polymerase (RNAP), which consists of five subunits in bacteria (2 x α, β, β', and ω) ([@B1]). RNAP initiates RNA synthesis at a promoter (initiation), extends the nascent RNA (elongation), and releases the RNA at a terminator (termination) ([@B2]). Among *Escherichia coli (E. coli)* transcription factors, [N]{.ul}-[U]{.ul}tilization [S]{.ul}ubstances (Nus) A and G are the only ones known to affect both the speed of RNA chain elongation and termination ([@B3]). NusG (Spt5 in archaea and eukaryotes), the only universally conserved transcription factor, is composed of an N-terminal domain (NTD) flexibly connected to a C-terminal domain (CTD) (Supplementary Figure S1A) ([@B4],[@B5]). NusG-NTD interacts with the β' clamp helices (β'CH) and the β gate loop (βGL) of RNAP to increase RNAP processivity ([@B4],[@B6],[@B7]). NusG-CTD is target of at least two cellular partners, termination factor Rho and antitermination factor NusE, which is identical to ribosomal protein S10 ([@B8],[@B9]). NusA comprises an NTD that binds to the β flap tip helix of RNAP at the RNA exit channel, three RNA binding motifs (S1, KH1, KH2) that together form the SKK domain, and, in *E. coli* and other γ-proteobacteria, two additional C-terminal acidic repeat domains (AR1, AR2; Supplementary Figure S1B) ([@B10]--[@B14]). NusA-AR1 interacts with N protein of phage λ, but is not essential for N-mediated suppression of transcription termination (antitermination) ([@B15]--[@B17]). NusA-AR2 can bind either to the CTD of the RNAP α-subunit (αCTD) or to the NusA-SKK. NusA-AR2 attached to NusA-SKK autoinhibits NusA activity by preventing RNA binding ([@B15],[@B18]).

NusA and NusG differentially alter the properties of the transcription elongation complex (TEC) *via* direct and independent interactions ([@B3]). NusG increases TEC processivity whereas NusA slows RNAP by either increasing pause times or by introducing new pause sites ([@B19]). The two factors have context-dependent effects on termination and act either in concert or as antagonists. On the one hand, NusG and NusA are proposed to support Rho cooperatively to suppress the toxic functions of foreign genes. On the other hand, both are part of antitermination complexes on ribosomal RNA and phage λ nascent transcripts ([@B20]--[@B23]). Furthermore, NusA can enhance or decrease both Rho-dependent and intrinsic termination efficiency, depending on the specific terminator (reviewed in ([@B24],[@B25])). NusG, in contrast, enhances termination exclusively at Rho-dependent sites ([@B26],[@B27]). Importantly, NusG serves as the physical linker between the RNAP and the ribosome by binding RNAP *via* NusG-NTD and S10 *via* NusG-CTD, thus coupling transcription and translation ([@B8]).

NusA and NusG bind to different sites on RNAP ([@B6],[@B7],[@B10]). Although these sites are in close proximity, a direct connection between the two factors has not been reported thus far. With nuclear magnetic resonance (NMR) spectroscopy we here demonstrate that NusA and NusG do specifically mutually interact and, supported by *in vivo* and *in vitro* data, we propose that this interaction may have key regulatory roles in diverse steps of transcription.

MATERIALS AND METHODS {#SEC2}
=====================

Cloning {#SEC2-1}
-------

*nusA* was cloned into the pTKK19 expression vector ([@B28]) *via* NdeI and BamHI restriction sites resulting in the recombinant plasmid pTKK19_nusA(1-495). The recombinant protein carried a deca-histidine tag followed by a PreScission cleavage site at its N-terminus.

Gene expression and protein purification {#SEC2-2}
----------------------------------------

Gene expression and protein purification procedures for NusG, NusG-NTD, NusG-CTD, NusA-NTD, NusA-SKK, NusA-AR1 and αCTD were described earlier ([@B8],[@B16],[@B29]--[@B32]). NusA-AR2 (NusA(424--495)) was produced as fusion protein with His~10~ tag followed by PreScission protease cleavage site at its N-terminus. Its gene expression and protein purification were according to the protocol for NusA(339-495) ([@B33]). His~10~-NusA-AR2 was purified like NusA-AR2 omitting the tag-removal step.

*nusA* was expressed in *E. coli* BL21 (DE3) harboring pTKK19_nusA(1-495). Cells were grown in lysogeny broth (LB) medium containing 30 μg/ml kanamycin at 37°C. At an optical density at 600 nm (*OD*~600~) of ∼0.7 expression was induced by 1 mM isopropyl-thiogalactoside (IPTG). Cells were harvested after 4 h (9,000 x *g*, 15 min, 4°C), resuspended in buffer A (20 mM Tris(hydroxymethyl)aminomethane (Tris)/HCl, pH 7.9, 500 mM NaCl, 5 mM imidazole, 1 mM β-mercaptoethanol) and disrupted by a microfluidizer (Microfluidics, Newton, MA, USA). After centrifugation (12,000 x *g*, 30 min, 4°C) the crude extract was applied to a 5 ml HisTrap HP column (GE Healthcare, Munich, Germany) and eluted using a step gradient from 5 mM to 1 M imidazole in buffer A. Fractions containing the His~10~-NusA fusion protein were combined and the protein was cleaved by PreScission protease during dialysis against buffer B (20 mM Tris/HCl, pH 8, 1 mM β-mercaptoethanol) at 4°C overnight. The protein solution was applied to a 5 ml GSTrap FF column (GE Healthcare, Munich, Germany) and the flow-through subsequently to a 5 ml QXL column (GE Healthcare, Munich, Germany). NusA was eluted using a step gradient from 0 to 1 M NaCl in buffer B. Fractions containing pure NusA were combined, dialyzed against 5 l 20 mM Tris/HCl, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol (DTT), concentrated using ultrafiltration units (Viva Science, molecular weight cut-off (MWCO): 10 kDa), shock frozen in liquid nitrogen, and stored at −80°C.

Production and purification of RNAP for NMR experiments was based on Ref. ([@B34]). In brief, *E. coli* BL21(DE3) (Novagen, Madison, WI, USA) harboring a plasmid containing *rpoA, rpoB, rpoC* and *rpoZ* in one operon under control of T7 promoter was used for gene expression. The β' subunit was produced as fusion protein carrying a His~6~ tag at its C-terminus. 2 l of LB medium in a 5 l flask supplemented with 100 μg/ml ampicillin were inoculated with an overnight culture to an OD~600~ of 0.02 and incubated at 37°C and 150 rpm. Having reached an OD~600~ of 0.2 the temperature was decreased to 20°C. After 2 h, IPTG was added to a final concentration of 0.5 mM for induction, and the culture was incubated overnight. Cells were then harvested by centrifugation for 15 min at 4°C and 9,000 x *g*, resuspended in buffer C (50 mM Tris/HCl, pH 6.9, 0.5 M NaCl, 5 % (v/v) glycerol, 1 mM DTT) and lysed with a microfluidizer (Microfluidics, Newton, MA, USA). RNAP was purified by nickel affinity chromatography with 2×5 ml Ni^2+^-nitrilotriacetic acid (NTA) Superflow columns (QIAGEN) and eluted by a constant gradient from 0 to 1 M imidazole in buffer C. Peak fractions containing RNAP were dialyzed against buffer D (50 mM Tris/HCl, pH 6.9, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 5 % (v/v) glycerol, 1 mM DTT) overnight at 4°C and then applied to a 5 ml Heparin HP column (GE Healthcare), followed by elution with a constant NaCl gradient from 0 to 1 M NaCl in buffer D. Fractions containing RNAP were pooled, dialyzed against buffer B overnight at 4°C, applied to a 25 ml Q-Sepharose FF column, and eluted with a constant gradient from 0 to 1 M NaCl in buffer B. RNAP containing fractions were concentrated using ultrafiltration units (Viva Science, MWCO: 10 kDa), shock frozen in liquid nitrogen, and stored at −80°C.

Production and purification of RNAP for *in vitro* transcription assays was carried out as described ([@B35]), with minor modifications.

Isotopic labeling of proteins {#SEC2-3}
-----------------------------

Proteins were uniformly labeled with ^15^N or ^15^N,^13^C by growing *E. coli* in M9 minimal medium ([@B36],[@B37]) supplemented with (^15^NH~4~)~2~SO~4~ (Campro Scientific, Berlin, Germany) or (^15^NH~4~)~2~SO~4~ and ^13^C-D-glucose (Cambridge Isotope laboratories, Inc., Andover, MA, USA) as the only nitrogen and carbon source, respectively. Expression and purification procedures were identical to those used for proteins produced in LB medium.

Pull-down assay {#SEC2-4}
---------------

The pull-down assay was performed with a 1 ml HisTrap HP column (GE Healthcare) equilibrated with buffer E (10 mM potassium phosphate, pH 6.9, 50 mM NaCl). The proteins were dialyzed against buffer E overnight at 4°C before application to the column. The application volume was always 1 ml. After extensive washing with buffer E, elution was carried out with 100 or 400 mM imidazole in buffer E, respectively, and resulted in a mixture of His~10~-NusA-AR2 and NusG-NTD (400 μM and 200 μM, molar ratio: 2:1) as assayed, with His~10~-NusA-AR2 (200 μM) alone and NusG-NTD (400 μM) alone as controls.

*In vitro* transcription assay {#SEC2-5}
------------------------------

RNA and DNA oligonucleotides were commercially synthesized by Integrated DNA Technologies with sequences derived from the T7A1 promoter sequence. Assembly of the TEC and the *in vitro* transcription were carried out as described ([@B38]). Briefly, a 65mer template DNA strand was hybridized to an 11mer RNA labeled with ^32^P at the 5′ end. 50 pmol RNAP in transcription buffer (TB, 20 mM Tris/HCl, pH 7.9, 5 mM MgCl~2~, 40 mM KCl, 2 mM β-mercaptoethanol) were mixed with equimolar concentrations of the DNA:RNA hybrid, followed by addition of the nontemplate DNA strand. The assembled TECs were purified by affinity chromatography using Ni^2+^-nitrilotriacetic acid agarose (QIAGEN) and subsequent membrane filtration with Ultrafree^©^ 0.65 μm PVDF centrifugal filters (Millipore). 2.5 μM TEC were incubated with 50 μM of one or both transcription factors or TB for 10 min at 25°C. When two proteins were tested they were added simultaneously, as previous tests indicated that the order of addition had no effect. Transcription was initiated by addition of 1 mM NTPs and stopped after 60 seconds by addition of an equal volume of 2x loading buffer (10M urea, 50 mM EDTA, pH 7.9, 0.05 % (w/v) bromophenol blue, and 0.05 % (w/v) xylene cyanol). RNA products were resolved on a 23 % denaturing polyacrylamide gel containing 7 M urea. Gels were exposed to phosphor screens and scanned by Typhoon Phosphorimager (GE Healthcare Life Sciences).

NMR experiments {#SEC2-6}
---------------

All NMR spectra were recorded at 298 K on Bruker Avance 700 MHz and Avance 800 MHz spectrometers with cryogenically cooled triple-resonance probes equipped with pulsed field-gradient capabilities. Processing of NMR data was carried out using in-house routines and visualized by NMRView ([@B39]). For all NMR experiments the proteins were in 10 mM potassium phosphate buffer, pH 6.4, 50 mM NaCl, at 298 K. The initial sample volume was 550 μl if not stated otherwise. Backbone assignments of NusG-NTD, NusG-CTD, NusA-AR2, and αCTD were taken from previous studies ([@B4],[@B18],[@B32]).

To evaluate \[^1^H,^15^N\]-heteronuclear single quantum coherence (HSQC) titration experiments we calculated the normalized chemical shift changes (Δ*δ*~norm~) according to Equation ([1](#M1){ref-type="disp-formula"}). $$\documentclass[12pt]{minimal}
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Dissociation constants (*K*~D~) were calculated from \[^1^H,^15^N\]-HSQC titrations by analyzing the chemical shift changes and fitting a two-state model as in Equation ([2](#M2){ref-type="disp-formula"}) to the chemical shift change of amide protons showing fast exchange on the chemical shift timescale. $$\documentclass[12pt]{minimal}
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}{}\begin{equation*}{\Delta \nu = \Delta {\nu _{{\rm{End}}}} \cdot \frac{{{{[P]}_{\rm{0}}} \cdot r + {{[P]}_{\rm{0}}} + {K_D} - \sqrt {{{\left( {{K_D} + {{[P]}_{\rm{0}}} + {{[P]}_{\rm{0}}} \cdot r} \right)}^{\rm{2}}} - {\rm{4}} \cdot ({{[P]}_{{{\rm{0}}}})^{\rm{2}}} \cdot r} }}{{{\rm{2}} \cdot {{[P]}_{\rm{0}}}}}}\end{equation*}\end{document}$$ where Δ*ν* is the normalized resonance frequency difference in Hz, Δ*ν*~End~ the normalized resonance frequency difference between free and fully bound protein in Hz, *K*~D~ the dissociation constant, *r* the protein:labeled protein ratio and \[P\]~0~ the total concentration of ^15^N-labeled protein. *K*~D~ and Δ*ν*~End~ were used as fitting parameters. The reduction of \[P\]~0~ due to dilution was accounted for during fitting.

For the displacement experiment of ^15^N-NusA-AR2 from αCTD by NusG-NTD separate samples were prepared for ^15^N-NusA-AR2 (100 μM, 500 μl) and ^15^N-NusA-AR2: αCTD (100 μM each, 500 μl). NusG-NTD was then added to the latter sample from a 287 μM stock solution.

For the quantitative analysis of signal intensities in the displacement experiments signal intensities were normalized by the number of scans, the concentration, and the length of the 90° proton pulse.

Docking {#SEC2-7}
-------

The complex of NusA-AR2 and NusG-NTD was modeled with the HADDOCK webserver ([@B40]) using data from the \[^1^H,^15^N\]-HSQC titrations as restraints (active residues in NusG-NTD: 4, 13, 15, 18, 44, 50, 51, 52, 58, 59, 61, 95, 104, 105, 106, 107, 109, 114, 117 and 118; active residues in NusA-AR2: 463, 474, 483, 487, 489, 490, 491 and 493). Passive residues were determined automatically. The NMR ensembles of NusA-AR2 (Protein Data Bank (PDB) ID: 1WCN) and NusG-NTD (PDB ID: 2K06) were used as input.

Strains and β-galactosidase assays {#SEC2-8}
----------------------------------

Strains were derivatives of MDS42, which lacks prophages and insertion elements ([@B41]) containing λ fusions ([@B42]). *lacZ* is expressed from the fusions *λcI857 -- pR -- cro(ΔRBS) -- nutR -- tR1 -- cII::lacZ* or *λcI857 -- pR -- cro~27~ -- nutR -- tR1 -- cII::lacZ*. The TAAGGAGGTTGT to TaccctccTTGT substitution in the *cro* ribosome binding site (RBS), blocks *cro* translation in the former strain (*cro(ΔRBS)*). *cro*~27~ has an RBS, but Cro~27~ is non functional due to an amino acid exchange (R27Q). The creation of strains 10323 and 10881 was described previously ([@B18]). The *rhoE134K* mutation was introduced by phage P1 transduction, resulting in a Rho variant which is non functional at λ*tR1*. The strains carrying *nusA* variants were constructed by recombineering.

Cells were assayed for β-galactosidase activity (Miller units) after overnight growth at 37°C. β-galactosidase activity of cells with defective Rho (*rho15*) was set to 100 % (strains 11633 and 11634), since termination was completely abolished at *λtR1*. Assays were performed independently four times and resulting activities were averaged.

Programmes {#SEC2-9}
----------

Graphical representations of protein structures were created with PyMOL ([@B43]). Sequence alignments were done with Clustal omega ([@B44]).

RESULTS AND DISCUSSION {#SEC3}
======================

NusG interacts specifically with NusA {#SEC3-1}
-------------------------------------

First, we probed a possible NusA:NusG interaction by NMR spectroscopy with full-length proteins. Addition of NusA to ^15^N-labeled NusG to equimolar concentration resulted in a strong decrease of NusG-NTD signals in the \[^1^H,^15^N\]-HSQC spectrum, whereas NusG-CTD signals were weakened only marginally (Figure [1A](#F1){ref-type="fig"}). The high transversal relaxation rate of the 54.9 kDa NusA strongly affects magnetization transfer efficiency upon binding, which leads to line broadening and ultimately to a decrease of signal intensity. Thus, the observed loss of NusG-NTD signals suggests direct NusA:NusG-NTD interaction. Specific NusA:NusG-NTD complex formation was confirmed by addition of NusA to either isolated ^15^N-NusG-NTD or ^15^N-NusG-CTD as signal loss was only observed for ^15^N-NusG-NTD (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). \[^1^H,^15^N\]-HSQC spectra of a 2-fold molar excess of ^15^N-NusG-NTD in the presence of isolated NusA-NTD, NusA-SKK, NusA-AR1, or NusA-AR2 clearly showed that, of these, only NusA-AR2 interacted directly with NusG-NTD (Figure [2](#F2){ref-type="fig"}).

![NusG-NTD interacts with NusA. \[^1^H,^15^N\]-HSQC spectra of (**A**) ^15^N-NusG, (**B**) ^15^N-NusG-NTD and (**C**) ^15^N-NusG-CTD before, black, and after, red, addition of NusA in equimolar concentration. Numbers in (**A**) represent the corresponding amino acid number of NusG with NusG-NTD signals in red and NusG-CTD signals in black. The concentration of the NusG construct was 50 μM in all experiments.](gkw423fig1){#F1}

![NusG-NTD interacts with NusA-AR2. \[^1^H,^15^N\]-HSQC spectra of ^15^N-NusG-NTD in the absence, black, or presence, red, of (**A**) NusA-NTD, (**B**) NusA-SKK, (**C**) NusA-AR1, and (**D**) NusA-AR2. ^15^N-NusG-NTD was present at 100 μM in all experiments, and NusA domains were added in a twofold molar excess.](gkw423fig2){#F2}

To corroborate the results of the NMR experiments, a pull-down assay was performed with decahistidine-tagged NusA-AR2 (His~10~-NusA-AR2) and untagged NusG-NTD (Supplementary Figure S2). NusG-NTD eluted from the nickel column together with His~10~-NusA-AR2, thus confirming the direct interaction between the two domains.

The NusG-NTD:NusA-AR2 complex {#SEC3-2}
-----------------------------

From the chemical shift perturbations of \[^1^H,^15^N\]-HSQC NMR titrations the *K*~D~-value of the NusG-NTD:NusA-AR2 interaction can be estimated to be 24 μM (Figure [3A](#F3){ref-type="fig"}, Supplementary Figure S3). By mapping the normalized chemical shift changes on the three-dimensional structures of NusG-NTD and NusA-AR2 the interaction interface can be located in the C-terminal part of helix α5 of NusA-AR2, markedly involving W490 and F491 (Figure [3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}). Although NusA-AR1 and NusA-AR2 share high sequence identity (31.5%) and have virtually identical three-dimensional structures with a root mean square deviation of main chain atoms of 1.2 Å (Supplementary Figure S4), NusG-NTD recognizes NusA-AR2 exclusively (Figure [2](#F2){ref-type="fig"}). This selectivity can probably be attributed to the presence of W490 and F491 in NusA-AR2, since Leu and Ala are found at corresponding positions in NusA-AR1 (Supplementary Figure S4). Different binding specificities for NusA-AR1 and NusA-AR2 to λ protein N and the αCTD of RNAP have been noted earlier ([@B13],[@B16],[@B18]). NusG-NTD signals from residues in the C-terminal helix α3' (aa 104--117) and in the elongated loop region between α1' and β1' (aa 48--68) are mainly affected by the NusG-NTD:NusA-AR2 interaction (Figure [3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}). Based on these binding surfaces a docking model without conformational rearrangements of the complex was generated (Figure [3C](#F3){ref-type="fig"}). Remarkably, the NusA-AR2 binding site on NusG-NTD is also involved in the NusG-NTD:RNAP β'CH interaction (Supplementary Figure S5) ([@B7],[@B45]). Furthermore, NusA-AR2 residues responsible for NusG-NTD binding are necessary for the interaction with αCTD (Supplementary Figure S6) ([@B18]). Thus, formation of the NusG-NTD:RNAP and NusG-NTD:NusA-AR2 complex is mutually exclusive, as is formation of the NusG-NTD:NusA-AR2 and NusA-AR2:RNAP complex.

![NusG-NTD:NusA-AR2 complex formation. (**A**, left) Sections of the \[^1^H,^15^N\]-HSQC-spectra of the titration of 140 μM ^15^N-NusG-NTD with NusA-AR2. NusA-AR2 was added in a molar ratio of 1:0, black, 1:0.75, red, 1:1.25, orange, 1:2.5, magenta, and 1:3.5, cyan (stock concentration of NusA-AR2: 1.1 mM). (right) Sections of the \[^1^H,^15^N\]-HSQC-spectra of the titration of 100 μM ^15^N-NusA-AR2 with NusG-NTD. Spectra corresponding to molar ratios 1:0, 1:0.5, 1:1, 1:2.5, and 1:3 are in black, red, orange, magenta, and cyan, respectively (stock concentration of NusG-NTD: 300 μM). Arrows indicate chemical shift changes during the titrations, selected signals are assigned. (**B**) HSQC-derived normalized chemical shift changes versus sequence position. (Left) Δ*δ*~norm~ of ^15^N-NusG-NTD on titration with NusA-AR2; (right) Δ*δ*~norm~ of ^15^N-NusA-AR2 on titration with NusG-NTD. Horizontal lines: significance levels of Δ*δ*~norm~ (ppm) = 0.12, red; = 0.08, orange; = 0.04, blue. (**C**) Model of the NusA-AR2:NusG-NTD complex. The complex was generated with HADDOCK using the chemical shift perturbations of the \[^1^H,^15^N\]-HSQC titrations as restraints. The model with the best HADDOCK score is depicted. NusA-AR2 (PDB ID: 2K06), blue, and NusG-NTD (PDB ID: 1WCN), grey, are in cartoon representation. The normalized chemical shift changes from (**B**) are mapped on the structures (0.04 ppm \< Δ*δ*~norm~ \< 0.08 ppm, yellow; 0.08 ppm \< Δ*δ*~norm~ \< 0.12 ppm, orange; Δ*δ*~norm~ \> 0.12 ppm, red). Panels show the surface representations of NusG-NTD, left, and NusA-AR2, right.](gkw423fig3){#F3}

NusG-NTD:RNAP versus NusG-NTD:NusA-AR2 versus NusA-AR2:RNAP {#SEC3-3}
-----------------------------------------------------------

We asked if NusG-NTD:NusA-AR2 interaction can take place in the presence of RNAP. Therefore a \[^1^H,^15^N\]-HSQC displacement experiment with isolated αCTD was performed (Figure [4A](#F4){ref-type="fig"},[B](#F4){ref-type="fig"}). Addition of NusA-AR2 to ^15^N-αCTD to equimolar concentration induced the chemical shift perturbations of ^15^N-αCTD signals observed earlier for this interaction ([@B18]). Stepwise addition of NusG-NTD to a final three-fold molar excess of NusG-NTD partially reversed these shifts, indicating that NusG-NTD can displace NusA-AR2 from the αCTD. Although the displacement was incomplete due to the lower *K*~D~ of NusA-AR2:αCTD (*K*~D~ \< 5 μM) ([@B18]) versus NusA-AR2:NusG-NTD (*K*~D~: 24 μM), it confirms that the RNAP/NusA-AR2 binding sites on NusG-NTD overlap as do the αCTD/NusG-NTD interaction interfaces on NusA-AR2. This finding was counter-checked by the displacement of ^15^N-NusA-AR2 from αCTD by NusG-NTD (Supplementary Figure S7). Addition of αCTD to ^15^N-NusA-AR2 to equimolar concentration resulted in chemical shift changes of signals from ^15^N-NusA-AR2 typical for ^15^N-NusA-AR2:αCTD complex formation ([@B18]). Subsequent addition of NusG-NTD caused the ^15^N-NusA-AR2 signals to shift towards the resonance positions of the ^15^N-NusA-AR2:NusG-NTD complex. Again, the displacement was incomplete owing to the difference in the affinities of NusA-AR2 to αCTD and NusG-NTD.

![NusG-NTD:NusA-AR2 interaction in the presence of RNAP. (**A** and **B**) \[^1^H,^15^N\]-HSQC displacement experiment of NusA-AR2 from ^15^N-αCTD by NusG-NTD. Black, ^15^N-αCTD; red, ^15^N-αCTD:NusA-AR2 = 1:1; blue, ^15^N-αCTD:NusA-AR2:NusG-NTD = 1:1:3. The concentration of ^15^N-αCTD was always 50 μM. The rectangle in (**A**) indicates the section as in (**B**). The arrows in (**B**) show the changes in the chemical shifts of selected residues. (**C**) NusG binds to NusA in the presence of RNAP. \[^1^H,^15^N\]-HSQC spectra of ^15^N-NusG, black, ^15^N-NusG in the presence of NusA (molar ratio 1:1), red, and ^15^N-NusG in the presence of NusA and RNAP (molar ratio 1:1:1), cyan. (**D**) NusG binds to NusA-AR2 in the presence of RNAP. \[^1^H,^15^N\]-HSQC spectra of ^15^N-NusG, black, ^15^N-NusG in the presence of NusA-AR2 (molar ratio 1:1), red, and ^15^N-NusG in the presence of NusA-AR2 and RNAP (molar ratio 1:1:1), cyan. Selected signals are labeled (black, NusG-NTD signals; red, NusG-CTD signals). The concentration of ^15^N-NusG was 50 μM in all experiments in (**C**) and (**D**). (**E**) NusA-AR2 removes NusG-NTD from RNAP. \[^1^H,^15^N\]-HSQC spectra of ^15^N-NusG-NTD, black, ^15^N-NusG-NTD in the presence of RNAP (molar ratio 1:0.5), red, and ^15^N-NusG-NTD in the presence of RNAP and NusA-AR2 (molar ratio 1:0.5:8), cyan. The concentration of ^15^N-NusG was always 50 μM. The rectangle in (**E**) indicates the section as in (**F**). In (**F**), selected signals are assigned with arrows indicating changes in their chemical shifts corresponding to the complex formation of ^15^N-NusG-NTD and NusA-AR2.](gkw423fig4){#F4}

We extended these studies to full-length proteins step-by-step. In an initial experiment we added RNAP to ^15^N-NusG, which led to a loss of almost all ^15^N-NusG signals in the \[^1^H,^15^N\]-HSQC spectrum owing to the dramatic increase of the NusG rotational correlation time upon formation of the NusG:RNAP complex (Supplementary Figure S8A). Although NusG-NTD is only flexibly linked to NusG-CTD and NusG is supposed to interact with RNAP *via* NusG-NTD ([@B4]), NusG-CTD signals were not observable in the ^15^N-NusG:RNAP complex. Thus, either NusG-CTD is sterically hindered in the complex so that it cannot move freely, or NusG-CTD interacts directly with RNAP. To exclude such direct NusG-CTD:RNAP interaction, we monitored isolated ^15^N-NusG-CTD in the presence of RNAP in a separate experiment and found no changes in the \[^1^H,^15^N\]-HSQC spectra as compared to ^15^N-NusG-CTD alone (Supplementary Figure S8B). Consequently, the loss of all ^15^N-NusG signals upon RNAP addition solely originates from formation of the NusG-NTD:RNAP complex.

To probe the NusA:NusG interaction in the presence of full-length RNAP we added NusA to ^15^N-NusG, leaving only NusG-CTD signals visible (Figure [4C](#F4){ref-type="fig"} and Supplementary Figure S8C). On addition of RNAP all signals decreased (Figure [4C](#F4){ref-type="fig"} and Supplementary Figure S8C). Thus, either (i) NusA:NusG interaction is disrupted by RNAP and both NusA and NusG bind individually to RNAP, or (ii) NusA:NusG remains intact and interacts with RNAP *via* NusA-NTD, or (iii) both. To eliminate interference by NusA-NTD:RNAP interactions, we repeated the experiment using isolated NusA-AR2 instead of full-length NusA (Figure [4D](#F4){ref-type="fig"} and Supplementary Figure S8D). When NusA-AR2 was present, the \[^1^H,^15^N\]-HSQC spectrum of ^15^N-NusG showed chemical shift changes corresponding to NusG-NTD:NusA-AR2 complex formation (see also Figure [2D](#F2){ref-type="fig"}). On addition of RNAP the intensity of the NusG signals decreased, however, in contrast to the experiment with full-length NusA, both NusG-NTD and NusG-CTD signals remained visible with the chemical shifts of the NusG-NTD:NusA-AR2 complex. We conclude (i) that at least some of the NusG-NTD:NusA-AR2 complexes remain intact in the presence of RNAP and (ii) that these complexes cannot bind to RNAP in the absence of NusA-NTD. This confirms that NusA-AR2:NusG and NusG:RNAP formation are mutually exclusive. The decrease in signal intensity may be explained by dissociation of a certain portion of the NusG-NTD:NusA-AR2 complex so that NusG binds to RNAP, and NusA-AR2 either interacts with the αCTD of RNAP or remains free. Thus, with full length NusA, the NusG:NusA complex is stable and is connected to RNAP *via* NusA-NTD, although a fraction of NusG and NusA might interact with RNAP individually.

We next demonstrated that NusA-AR2 can remove NusG-NTD from RNAP (Figure [4E](#F4){ref-type="fig"}). As expected, ^15^N-NusG-NTD signals were drastically diminished by addition of RNAP. However, they reappeared upon NusA-AR2 addition with the chemical shift perturbations typical for the NusG-NTD:NusA-AR2 complex. Hence, NusA-AR2 and RNAP compete for NusG-NTD.

NusA-AR2 induces pausing and blocks NusG suppression of pausing *in vitro* {#SEC3-4}
--------------------------------------------------------------------------

We then asked if the NusA-AR2:NusG-NTD interaction affects transcription *in vitro*. For this we utilized a nucleic acid scaffold to generate a transcription elongation complex (TEC) which carries an 11 nt ^32^P-labeled RNA primer base-paired to template DNA and flanked by non-template DNA (TEC11A, for details see Materials and Methods). Transcription was initiated by the addition of the four NTPs and stopped after 60 seconds. The TEC paused at several intrinsic pause sites in the template in the absence of additional transcription factors, with pause 1 being the most prominent (Figure [5](#F5){ref-type="fig"}; lane 2). Full-length NusG suppressed pause 1, increased run-off transcription and introduced a weak new pause, pause 2 (lane 3). NusA-AR2, interestingly, generated a strong pause at position 12C (pause 3), 1 nt downstream of the transcription start site, without influencing other pause sites (lane 4). Moreover, NusA-AR2 completely blocked run-off transcription (lane 4). When both proteins were present in equimolar amounts, pause 2 was enhanced, whereas pause 1 and run-off transcripts were suppressed (lane 5). Enhancement of NusG-dependent pause 2 is consistent with an interaction between NusG and NusA-AR2, possibly explained by the inability of NusG-NTD to enhance processivity when bound to NusA-AR2. The NusA-AR2-dependent pause 3 was not influenced by NusG (lane 5). NusG-NTD yielded similar results as full-length NusG. It suppressed pause 1 (lane 6), and this suppression was abrogated by NusA-AR2 (lane 7). As with full-length NusG, NusG-NTD did not affect NusA-AR2-induced pause 3 (lane 7).

![*In vitro* transcription assay for combinations of NusG, NusA, NusG-NTD and NusA-AR2. 23 % urea-polyacrylamide gel. The assembled TEC (TEC11A) was pre-incubated with NusG, NusA, NusA-AR2, NusG-NTD, combinations of these, or transcription buffer for 10 min at 25°C. Transcription was started by NTP addition and stopped after 60 s. TEC11A, run-off, and three pause sites are indicated by arrows.](gkw423fig5){#F5}

Full-length NusA enhanced pause 1, but did not, however, induce pausing at pause 3 (lane 8). This suggests that the NusA-AR2 domain in full-length NusA was still bound to the NusA-SKK domain, and was not free to interact with the initiating TEC. Unlike NusA-AR2, suppression of pause 1 by full-length NusG or NusG-NTD was not completely abrogated by full-length NusA, possibly because NusA-AR2 remains bound to the NusA-SKK domain during elongation, and is not available to interact with NusG-NTD (lanes 8--10).

The ability of isolated NusA-AR2 to pause the TEC at 12C (pause 3) was unexpected. It suggests that at least early in elongation, when RNA has not yet extruded from the exit channel, NusA-AR2 may still be bound to the SKK domain and may thus be unavailable to interact with αCTD. In addition, the ability of NusA-AR2 to induce a strong pause implies that NusA-AR2 might act as a regulatory element during elongation if dissociated from αCTD.

NusA-ΔAR2 blocks Rho-dependent termination at λ*tR1 in vivo* {#SEC3-5}
------------------------------------------------------------

NusA suppresses termination at certain Rho-dependent sites, e.g. within λ*tR1* ([@B46]). We propose that the NusA:NusG interaction contributes to this effect. To support this hypothesis we asked if a deletion of NusA-AR2 (NusA-ΔAR2) affected termination at λ*tR1 in vivo* (Figure [6](#F6){ref-type="fig"}). We performed β-galactosidase assays using two fusions to measure termination: *λcI857 -- pR -- cro(ΔRBS) -- nutR -- tR1 -- cII::lacZ* and *λcI857 -- pR -- cro~27~ -- nutR -- tR1 -- cII::lacZ*. Termination at λ*tR1* is indicated by low β-galactosidase activity. Strains carrying a mutation in the *rho* gene show no termination at λ*tR1*; β-galactosidase activity of these strains was thus set to 100%. The efficiency of termination at λ*tR1* was 93% when *cro* translation was prevented by an RBS mutation (strain 10323), and reduced to 74 % when *cro* was translated (strain 11149). Ribosomes reduce the amount of free RNA upstream to λ*tR1* that is available to Rho, and thus block a Rho-binding site (*rut*) in *cro* ([@B47]).

![Deletion of NusA-AR2 affects termination at λ*tR1*. β-galactosidase reporter assays were performed with *lacZ* fusions *λcI857 -- pR -- cro(ΔRBS) -- nutR -- tR1 -- cII::lacZ* and *λcI857 -- pR -- cro~27~ -- nutR -- tR1 -- cII::lacZ*. Strains are derivatives of *E. coli* MDS42. Cells were assayed for β-galactosidase activity (Miller units) after overnight growth at 37°C. β-galactosidase activity of cells with defective Rho was set to 100% (strains 11633 and 11634). *P* values are \< 0.05 (\*), \< 0.01 (\*\*), or \< 0.001 (\*\*\*). RBS +/−, functional/defective RBS; Rho +/−, functional/defective Rho; FL, full length.](gkw423fig6){#F6}

We found that termination efficiency was significantly impaired (50%) in the *nusA-ΔAR2* mutant only when *cro* mRNA was translated (compare strain 10881 to strain 10323 and strain 11699 to strain 11149). Our results suggest that NusA-ΔAR2 may compete with Rho binding near λ*nutR*, the only *rut* site available when the *cro* transcript is occluded by ribosomes. When *cro* is not translated, Rho can attach to the free *cro rut* site ([@B48]). Competition with Rho by NusA-ΔAR2 can be explained by constitutive binding of NusA-ΔAR2 to RNA *via* NusA-SKK. Consistent with the *in vitro* studies described above, this implies that full length NusA may still be, at least partially, in the autoinhibited state and unable to bind *rut* RNA at λ*tR1*. It also raises the possibility that NusG may activate RNA binding of full-length NusA by displacing NusA-AR2 from the NusA-SKK domain. Further experimentation will be needed to address these questions.

Possible regulatory functions of the NusG-NTD:NusA-AR2 interaction {#SEC3-6}
------------------------------------------------------------------

Transcription factors NusA and NusG act independently to slow or accelerate transcription elongation, respectively. The two factors can also function synergistically in restoring termination by the partially defective RhoE134K mutant ([@B49]). Here, however, we demonstrate a direct interaction between NusA and NusG. Formation of a complex between NusG-NTD and NusA-AR2 may explain their various *in vivo* and *in vitro* combinatorial regulatory effects (Figure [7](#F7){ref-type="fig"}). Figure 7.Possible functions of NusG:NusA interaction in transcription regulation. First, the NusA:NusG interaction may play a role in the recruitment of NusG to the TEC. Second, it may provide a long linker between RNAP and the ribosome consisting of NusA and NusG, which would allow resynchronization of transcription:translation coupling. Third, the NusG:NusA interaction may release the autoinhibition of NusA allowing constitutive binding of NusA-SKK to RNA, so that recruitment sites for Rho are blocked and Rho-dependent termination is decreased. Forth, NusA-AR2 may abstract NusG-NTD at intrinsic termination sites facilitating the release of nucleic acids and enhancing intrinsic termination. NusA-AR2 supports NusG recruitment.NusG:NusA interaction may be involved in recruiting NusG to the TEC. ChIP-chip data suggest that NusA and NusG associate with RNAP when the TEC has exited the promoter region, with NusG attaching after NusA does ([@B50]). The delay in NusG association may be due to a competition between σ^70^ region 2 and NusG-NTD, since both bind to the RNAP β'CH ([@B7],[@B51]--[@B53]). Recall that the σ^70^ region 2 can remain bound to the TEC even when σ^70^ region 4 has dissociated from the β flap, allowing NusA-NTD binding ([@B54],[@B55]). After promoter escape, NusA attaches to the αCTD *via* NusA-AR2, to the β flap *via* NusA-NTD, and to nascent RNA *via* NusA-SKK ([@B10],[@B15],[@B18],[@B56]). Thus, stable tethering of NusA to the TEC may not require continuous binding of NusA-AR2 to αCTD. NusA-AR2 could, therefore, bind NusG-NTD without disrupting the NusA:TEC complex. In this model, NusA serves as a long linker to increase the local concentration of NusG, facilitating NusG recruitment to the TEC and displacement of σ^70^ region 2 from the β'CH at the transition from initiation to elongation.NusG-NTD:NusA-AR2 interaction assists transcription:translation coupling.As a second function, we suggest that NusG:NusA interaction plays a role in coupling transcription and translation. NusG connects these two processes by physically linking RNAP and the leading ribosome *via* NusG-NTD:RNAP and NusG-CTD:S10 interactions ([@B4],[@B8]). The NusA:NusG interaction could serve to resynchronize transcription and translation by coordinating the movements of RNAP and the ribosome. If translation is slowed, transcription could likewise be slowed by the temporary removal of NusG-NTD from the TEC by NusA-AR2. Since the NusG:ribosome connection remains intact, transcription and translation can be kinetically resynchronized. Also, the initial coupling of transcription and translation may occur *via* the NusA:NusG linker. This would explain the apparent late association of NusG with the TEC, as detected by ChIP-chip experiments ([@B50]).NusG-NTD:NusA-AR2 interaction regulates transcription termination.The NusA:NusG interaction could influence context-dependent intrinsic or Rho-dependent transcription termination. In the former, the TEC pauses at an intrinsic termination signal, enters an elemental pause state, and then isomerizes into the termination state where the termination hairpin is formed ([@B57]). NusA-AR2 can remove NusG-NTD from RNAP, resulting in loss of both NusA-AR2 and NusG-NTD contacts to the TEC (Figure [4E](#F4){ref-type="fig"}). Loss of these interactions might partially destabilize the TEC, open the clamp around the nucleic acids, and facilitate intrinsic termination. In contrast, the NusA-AR2:NusG-NTD interaction might decrease Rho-dependent termination. Binding of NusA-AR2 to NusG-NTD would release NusA autoinhibition, enhancing binding of NusA-SKK to nascent RNA to block Rho recruitment.

The *K*~D~ values for the various interactions suggest that scenario 1 is the most probable. This scenario is also consistent with a global survey of distribution of transcription factors ([@B50]). The relevance of NusG-NTD:NusA-AR2 interaction in detail will need further experimental clarification, but the finding that NusG interacts directly with NusA may explain the various effects of these transcription factors on elongation and termination reported here and earlier.
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